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Cast nephropathy, also known as Myeloma Kidney, is a frequent complication of 
Multiple Myeloma. It results from the interaction of excess free immunoglobulin light 
chains (FLC) with Tamm-Horsfall protein in the distal tubule and thick ascending limb 
of the loop of Henle, forming dense, mucous, casts, which cause tubular obstruction and 
rupture, resulting in local inflammation and fibrosis. The kidney injury is irreversible if 
appropriate therapy is not rapidly instituted. 
A prompt, sustained reduction of serum FLC concentration leads to improved renal 
recovery rates. However, the optimal therapeutic strategy to achieve this reduction is yet 
to be determined. While the role for chemotherapy and correction of precipitating 
factors is clear, the extracorporeal removal of FLCs is being investigated, with the use 
of high cut-off hemodialysis membranes particularly promising. 
 
 
A Nefropatia de Cilindros, também conhecida por Rim de Mieloma, é uma complicação 
frequente em doentes com Mieloma Múltiplo. Resulta da interação de cadeias leves de 
imunoglobulinas livres (FLCs) com a proteína de Tamm-Horsfall no túbulo contornado 
distal e ramo ascendente da ansa de Henle, formando cilindros densos e mucosos que 
causam obstrução e rutura tubular, que resulta em inflamação local e fibrose. A lesão 
renal é irreversível se a terapêutica apropriada não for rapidamente instituída. 
Uma diminuição mantida da produção de FLCs traduz-se em melhores taxas de 
recuperação da função renal. Contudo, a estratégia terapêutica óptima para conseguir 
aquela redução ainda não foi estabelecida. Enquanto que o papel da quimioterapia e da 
correção dos factores precipitantes é claro, a remoção mecânica das FLCs está a ser 






Multiple Myeloma (MM) is a disease defined by the proliferation of malignant 
plasmatocytes in the bone marrow, tumor-produced monoclonal protein in the blood or 
urine and associated organ dysfunction.1 The clinical presentation is typically 
dominated by the CRAB signs and symptoms, standing for hyperCalcemia, Renal 
failure, Anemia and Bone lesions (pain or fractures), but may also include susceptibility 
to infections, and, more rarely, neurological symptoms, clotting abnormalities and 
features of hyperviscosity. 
EPIDEMIOLOGY 
A rare cancer, MM is responsible for slightly less than 1% of all new cancer cases 
worldwide. Incidence rates are highest in developed countries in North America, Europe 
and Australia/New Zealand, where its incidence can be almost 5 per 100 000 persons. 
Incidence is low in Asia, except western Asia.2 In Portugal, there are approximately 520 
new cases and 360 deaths per 
year due to multiple 
myeloma, corresponding to 
1% of all new cancers and 
1.5% of cancer deaths.3 MM 
corresponds to 10-15% of 
hematological malignancies. 
 
It is slightly more common 
in males than females, with a worldwide incidence ratio of 1.4/1. In the USA, it affects 
people of African-American descent approximately twice as much as whites, while 
people of Asian origin have a much lower incidence.4 
The median age at diagnosis is approximately 70 years. Despite differences in 
incidence, response to therapy and prognosis are similar across different ethnicities. 
ETIOLOGY 
The etiology of MM is poorly understood, in part due to its low incidence. The presence 
of a first degree relative (but not second, or third-degree relatives) has shown an 
increased risk of developing multiple myeloma. Obesity and acquired immune 
Figure 1- Percent of New Multiple Myeloma Cases by Age Group, USA.4 
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deficiency syndrome (AIDS) are possible risk factors, as well as chronic exposure to 
ionizing radiation. Alcohol and tobacco consumption have shown inconsistent 
associations with risk of MM. Fish and seafood consumption appear to be protective 
factors. Additionally, a hormonal component is presumed, due to the higher incidence in 
males.5 
MOLECULAR BASIS OF DISEASE 
Multiple myeloma results from the abnormal malignant proliferation of plasma cells 
derived from a single post-germinal-centre B-cell clone. While it is often diagnosed de 
novo, most studies point to an evolution from the premalignant condition Monoclonal 
Gammopathy of Undetermined Significance, or MGUS.6 This condition is present in 3-
4% of the general population over 50 years of age, increases in prevalence with age, and 
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Figure 2 -  Multistep pathogenesis of Multiple Myeloma. Both MGUS (Monoclonal gammopathy of undetermined 
significance) and Multiple Myeloma share early chromosomal abnormalities, typically involving immunoglobulin heavy 
chain translocations or trisomies. Secondary translocations are quite rare in MGUS; activation of oncogenes such as 
RAS and FGFR3 and dysregulation of MYC and TP53 determine drug resistance and tumor progression. Besides the 
molecular changes in neoplastic plasmatocytes, changes of bone microenvironment, specifically resorption and 
aberrant angiogenesis are features of disease progression. 86 
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PATHOPHYSIOLOGY OF CAST NEPHROPATHY 
The M component 
The presence of a monoclonal protein is a 
defining feature of MM, presenting in 
almost all patients. While only 82% of 
patients will have a corresponding peak or 
band in serum protein electrophoresis 
(SPEP), 97% of patients will have a 
detectable M-component if immunofixation 
of serum or urine is performed in addition to 
SPEP.8 
However, up to 3% of patients will not have 
any detectable monoclonal protein in the 
blood or urine,8 traditionally defined as non-
secretory MM.9 Approximately 60-70% of 
these patients will, however, have an altered 
kappa/lambda ratio in a serum Free Light 
Chain (sFLC) assay.10–12  
The remainder will have true non-secretory 
myeloma, with 85% having evidence of 
cytoplasmic immunoglobulin on bone 
marrow immunofixation of plasmatocytes, 
but a defect in its secretion, and 15% will 
have non-producer myeloma.13 As 
immunoglobulins and free light chains are 
nephrotoxic, patients with non-secretory 
myeloma have no risk of Ig-mediated renal 
lesion.   
A review of 1027 patients revealed the 
following M-component distribution: 52% 
IgG, 21% IgA, 2% IgD, 0,5% IgM, 2% are 
Figure 4 – The typical four chain structure of a generic 
antibody (a) and the corresponding three-dimensional 
structure of the antibody IgG2 (b). The basic unit of an 
immunoglobulin is built of two identical heavy and two 
identical light chains, arranged in a symmetrical Y-
shape. Human Igs can belong to one of 5 classes 
(isotypes), IgA, IgD, IgE, IgG and IgM, which 
correspond respectively to alpha, delta, epsilon, 
gamma or mu class heavy chains. The light chains can 
be kappa or lambda. Both light and heavy chains have 
a variable region, corresponding to the antigen-binding 
site and a constant, structural region. 
Light chains have a molecular weight of approximately 
25 kDa. 88 
Figure 3 – Typical tracing of serum protein 
electrophoresis of a multiple myeloma patient, with M-
component present in the gamma region. Less often, it 
is in the beta or alpha-2. even more rarely, a biclonal 
peak can be seen.87 
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Bi-clonal and 16% contains only light chain, with kappa being twice as common as the 
lambda isotype. 
Light chain metabolism 
During normal Ig synthesis, light chains (LCs) are produced in slight excess to allow the 
correct assembly of the immunoglobulin.14 Up to 500-1000 mg of polyclonal Free Light 
Chains (FLC) produced each day by the immune system, released into circulation, 
freely filtered through the glomerulus and efficiently endocytosed by the epithelial cells 
of the proximal tubule, with less than 10 mg of polyclonal FLCs excreted in the urine 
each day.15 
In MM, there is an overproduction of FLCs, such that they exceed the proximal tubule’s 
catabolic capacity and are excreted in large quantities, classically described as Bence-
Jones proteinuria, after Henry Bence Jones, the physician who first described the 
protein in 1847.16 In the distal tubule, the FLCs interact with Tamm-Horsfall protein 
(THP), an 80 kDa glycoprotein of uncertain function secreted by cells in the thick 
ascending limb of the loop of Henle. A 9 amino acid sequence in THP binds to the 
complementarity determining region 3 (CDR3) of the FLC.17 As this is a variable 
region, different FLCs have varying nephrotoxic potential.  
The binding of FLCs to THP creates dense mucous casts, leading to tubular obstruction 
and rupture, resulting in subsequent interstitial inflammation, fibrosis, which define 
Cast Nephropathy (CN). 
Additionally, increased FLC 
concentration, decreased flow 
through the nephron (as in 
hypovolemia), acidic pH, loop 
diuretics promote FLC 
aggregation and lead to cast 
formation in animal 
models.18,19 Radiocontrast 
media, hypercalcemia and 
nephrotoxic drugs (such as 
non-steroidal anti-
inflammatory drugs and 
Figure 5- light microscopy of a kidney with cast nephropathy stained with 
PAS, with characteristic features of CN marked. * - casts, PAS negative. 
Some are fractured. The single-headed arrows mark inflammatory infiltrate 
in the kidney interstitium and surrounding the casts. The double headed 
arros mark an increase in distance between the tubules, due to edema 
(acute) or tubular atrophy (chronic).89 
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angiotensin-converting enzyme inhibitors) have 
also been implicated.18,20,21 In addition to cast 
formation, CN can present with proximal tubule 
damage. Some light chains are resistant to 
lysosomal degradation and accumulate in the 
proximal tubule cells.18,22 
If severe enough, the histological damage 
resulting from these processes will translate 
clinically to overt acute kidney injury (AKI). 
DIAGNOSIS 
Up to 25-50% of patients with MM will 
develop mild renal impairment during the 
course of the disease. AKI is frequently the inaugural manifestation, with up to 10% of 
patients dialysis-dependent at presentation.8,23 Renal insufficiency in MM has been 
defined by the International Myeloma Working Group as a creatinine clearance < 40 
mL/min as calculated by the CKD-EPI or MDRD equations or serum creatinine > 2 
mg/dL resulting from the disease.24 However, these equations are only validated in 
patients with stable creatinine levels, and the use of the AKIN or RIFLE criteria is 
recommended, with the caveat that they have not 
been studied in detail in MM patients.25 
Regarding the etiology of renal impairment, cast 
nephropathy is the most common etiology, 
responsible for 33 to over 60% of renal 
impairment in some series.26 Monoclonal 
immunoglobulin deposition disease and AL 
amyloidosis are the other major causes. However, 
a significant minority of patients may have renal 
impairment not related to MM, such as diabetic 
nephropathy or hypertensive arteriosclerosis.27 
Definitive diagnosis can be made by renal biopsy. 
However, it can often be distinguished from other 
Figure 6 – diagram of urine electrophoresis. The 
top figure corresponds to a selective proteinuria 
typical in cast nephropathy, while the bottom 
depicts the non-selective or predominantly 
albumin proteinuria of amyloidosis, monoclonal 
immunoglobulin deposition disease, and other 
unrelated entities. 
List 1 – Kidney diseases in multiple 
myeloma classified by site of injury 
90,91 
Glomerular 
• Primary amyloidosis (AL or AH) 
• Monoclonal immunoglobulin deposition 
disease (light chain, heavy chain or both) 




• Cast nephropathy 
• Distal tubular dysfunction 
• Acquired Fanconi syndrome 
 
Interstitial 
• Plasma cell infiltration 









causes noninvasively. The quantification and electrophoresis of a 24-hour urine sample 
can determine whether the proteinuria is selective for light chains, non-selective or 
albumin-rich. Monoclonal Immunoglobulin Deposition Disease (MIDD) and 
amyloidosis typically present with nephrotic syndrome (albumin preponderance). 
Therefore, in patients with high sFLCs (> 500 – 1500 mg/L) and significant Bence-
Jones proteinuria, a renal biopsy can often be discarded if there are no confounding 
factors. If the patient presents with nonselective proteinuria, significant albuminuria and 
low sFLC (< 500 mg/L) a renal biopsy will most likely be necessary to distinguish 
between the multiple entities.25 A biopsy of subcutaneous fat positive for Congo-red 
may diagnose amyloidosis. 
PROPHYLAXIS 
Various strategies have been employed to reduce the risk of developing CN in high-risk 
patients: vigorous hydration, avoidance of loop diuretics and alkalinization of urine. The 
latter has its physiologic basis in the manipulation of electric charges on FLCs to 
modulate their affinity for THP. The isoelectric point (iP) of FLCs is 5.1. By increasing 
the pH in the distal tubule above the iP, the FLCs would lose positive charges and have 
a reduced binding with the anionic THP.18,19 However, there is no evidence as to its 
effectiveness either in preventing CN in humans or aiding in its reversal in overt 
CN.18,28  
In order to specifically target pathological interaction of FLCs with THP, a cyclized 
peptide was synthesized which inhibited the binding of FLCs to THP in vitro and 
prevented the development of CN in an animal model.29 By simulating the CDR3 region 
of the FLCs and binding to the Light-Chain Binding Domain on THP,30 it was effective 
in preventing CN when co-administered with nephrotoxic light chains in mice, even 
when given 4 hours after the nephrotoxic light chains. While an innovative proof-of-
concept, only one of each type of light chain, kappa and lambda, was evaluated and 
similar trials are yet to be attempted in humans. 
TREATMENT STRATEGY 
As the development of acute kidney injury in CN is multifactorial, management should 
contain both general measures to correct precipitating and aggravating factors such as 
hypercalcemia and volume depletion as well as therapy targeted at reducing serum FLC 
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concentration. This includes chemotherapy to decrease production, as well as 
extracorporeal removal of the FLCs.  
General measures 
The principal objective of therapy is to decrease the concentration of light chains in the 
distal tubules and avoid their precipitation, to avoid further kidney injury. This can be 
achieved by correction of volume depletion, hypercalcemia, hyperuricemia and 
avoidance of nephrotoxic drugs (nonsteroidal inflammatory drugs, radiocontrast dye, 
angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists).25  
Typically, isotonic IV fluids are used for rehydration, with a bolus of 500-1000 mL and 
further administration at a rate of 100-200 mL/hour until the patient is euvolemic, with 
particular care to avoid volume overload in patients with congestive heart failure (CHF). 
Once the patient is euvolemic, administration should be titrated to a urine output of 100 
mL/hour.31 Furosemide was considered a mainstay of treatment by forcing diuresis, but 
this approach is not supported by evidence and enhances cast formation, so should only 
be considered in patients with CHF and clear signs of fluid overload.32 
Hypercalcemia leads to renal vasoconstriction and enhances cast formation.18 It 
normally courses with volume depletion, and should be treated accordingly.33 IV 
Bisphosphonates are a mainstay of severe hypercalcemia management. Both 
zoledronate (3-4 mg over 15-30 min) and pamidronate (60-90 mg over 2-6 hours) have 
been used in hypercalcemia combined with AKI.34–36 Dosage should be adjusted for 
renal function. Zoledronate is the more effective agent but has been associated with 
greater worsening of kidney function than pamidronate, so the latter may be preferred. 
Importantly, both may cause collapsing focal segmental glomerulosclerosis and acute 
tubular necrosis.37,38 
Bisphosphonates can take up to 48-72 hours to have effect on calcium levels. Therefore, 
for severe hypercalcemia, calcitonin can be used. The subcutaneous or intramuscular 
administration of 4-8 units/kg every 6-12 hours can reduce serum calcium levels by 2 
mg/dL for up to 72 hours, limited by the development of tachyphylaxis, with no 
adjustment for renal function required.39 
The alkalinization of urine is often attempted in many treatment centers. This treatment 
is not supported by evidence.28 
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Myeloma chemotherapy  
The key to effectively treating cast 
nephropathy is the prompt and significant 
decrease in FLC concentration. The 
current treatment paradigm is a 
bortezomib-based regimen, in conjunction 
with high dose corticosteroids in the first 
month and immunomodulatory drugs such as thalidomide and lenalidomide. While the 
specifics of myeloma chemotherapy go beyond the scope of this thesis, an overview of 
the current therapeutic options will be described. 
Bortezomib is effective at rapidly lowering FLC concentration and may be 
renoprotective by its effects on the NF-κB pathway in proximal tubule cells. It is not 
metabolized by the kidney and therefore does not require dose adjustment for renal 
impairment. Multiple studies have confirmed its benefits in renal response and time to 
renal response, dialysis independence and mortality. As such, it is considered a 
cornerstone of CN and MM therapy, comparing favorably to cytotoxic chemotherapy, 
lenalidomide and thalidomide based regimens.25,40 The subcutaneous administration 
appears to have similar results as intravenous, and leads to less adverse effects.41,42  
Other proteasome inhibitors are undergoing investigation, and have not proven to be 
superior to bortezomib. Both carfilzomib and ixazomib (the first oral proteasome 
inhibitor) have been studied in relapsed multiple myeloma and can be administered in 
patients with a creatinine clearance ≥ 30 mL/min.43,44 
High dose steroids (typically administered as 3 pulses of 40 mg dexamethasone given 4 
days on, 4 days off for a 28-day cycle)45,46 given during the first month of therapy have 
been associated with a more rapid renal response, in comparison with low dose steroids,  
(1.6 to 46 months) even in treatment regimens that included bortezomib and 
lenalidomide or thalidomide.47 
The immunomodulatory drugs currently in use, lenalidomide and thalidomide, have 
been shown to be safe and effective in MM associated renal impairment. While 
thalidomide does not require dose adjustment, lenalidomide has renal excretion and 
requires dosing modifications. Pomalidomide is ongoing study for use in moderate to 






Best CrCl Response 
(mL/min) 
Complete 
response < 50 ≥ 60 
Partial 
response < 15 30 - 59 
Minor 
response 
< 15 15 – 29 
15 – 29 30 – 59 
Abbreviations: CrCl, creatinine clearance; eGFR, 
estimated glomerular filtration rate based on the CKD-EPI 
or MDRD formula 
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severe renal impairment, having shown to be safe and effective in patients with GFR ≥ 
45 mL/min.25 
Renal impairment does not preclude autologous stem cell transplantation (ASCT), and 
is the treatment of choice in newly diagnosed MM patients eligible. An adjustment of 
the melphalan dose is required but appears to be equally effective.48 ASCT in patients 
with renal impairment at the time of the procedure is associated with a greater 
mortality.48–50 	
Extracorporeal FLC removal 
The FLCs have a molecular weight of approximately 25 kDa, and therefore their 
removal depends on either plasma exchange, or renal replacement therapy using 
membranes with pores of sufficient caliber: Hemofiltration or High Cut-Off 
hemodialysis. 
Importantly, these therapies depend on concomitant chemotherapy in order to cause a 
decrease in production of the FLCs. 
Plasma exchange 
The therapeutic exchange of plasma has been used experimentally in acute kidney 
injury associated with multiple myeloma since at least 1978 with conflicting results.51 
However, only 4 randomized clinical trials (RCT) have been done to address the issue 
of whether plasmapheresis adds any benefit to chemotherapy in MM-associated kidney 
injury. 
The oldest one included 29 patients, 16 of which had biopsy proven cast nephropathy. 
The control group (n=14, 11 dialysis-dependent) was offered chemotherapy with 
methylprednisolone and cyclophosphamide, as well as peritoneal dialysis if needed. The 
study group (n=15, 13 dialysis-dependent) was offered plasma exchange and 
hemodialysis as necessary in addition to identical chemotherapy. With 5-7 daily 
sessions, 13/15 (87%) patients in the trial group recovered renal function with serum 
creatinine levels decreasing to below 2.5 mg/dL, compared to only 2 patients (14%) 
becoming dialysis-independent in the control group. Survival at 1 year was improved in 
the plasmapheresis group (66 vs 28%).52 
A study by Johnson (n=21) forced diuresis with furosemide and chemotherapy with or 
without plasma exchange (n=11 and n=10, respectively) and found no significant 
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difference in overall survival or recovery of 
renal function; however, the plasmapheresis 
group had a much faster decrease of serum 
M-protein.53 
The largest trial with published results 
included 97 patients with acute renal 
impairment due to MM. 58 received 5-7 
plasma exchanges and chemotherapy with 
either melphalan-prednisolone or vincristine-
adriamycin-dexamethasone and 39 received 
only chemotherapy. After 6 months, there 
was no statistical difference between groups 
on the composite outcome of death, dialysis 
dependence or GFR < 30 mL/min (58% study 
vs 69% control).54 
Finally, the MERIT trial, having enrolled 
only 77 of the planned 286 patients, closed 
without publishing results.55 However, results 
presented at a meeting failed to show any 
benefit of plasmapheresis over conventional 
chemotherapy.56 
High cut-off hemodialysis 
High cut-off hemodialysis (HCO-HD) 
operates on the same principles as 
conventional dialysis, but uses a membrane 
with larger pores (typically around 0.008 to 
0.01 µm, compared to 0.003-0.006 µm for high-flux dialysis membranes). Molecules up 
to 50-60 kDa are filtered effectively, but due to lack of uniformity in pore size, the 
membranes will allow some loss of slightly larger molecules, such as albumin (66.5 
kDa)57. Kappa FLC monomers and lambda FLCs dimers, with molecular weights of 
22.5 and 45 kDa respectively, are effectively filtered by HCO-hemodialysis in vitro and 
in vivo.58  
Figure 7 – A: scanning electron microscopy of high-
flux, high cut-off and plasmafilter membrane surfaces. 
B: respective membrane pore size distribution.57	
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Several case reports and case series have been published, adding HCO-HD to 
chemotherapy and overall showing its effectiveness to quickly reduce FLCs in addition 
to chemotherapy. The largest published study to date enrolled 67 patients (biopsy-
confirmed CN in 37 of the 38 biopsied patients), and offered HCO-HD combined with 
chemotherapy (bortezomib-based in 58%). 63% of patients became dialysis 
independent. Interestingly, a significant association was found between dialysis 
independence and both initiation of dialysis within 7 days of renal failure and sustained 
FLC reduction by days 12 and 21.59 Another study prospectively evaluated 21 patients 
with CN-associated kidney injury (15/21 biopsy-confirmed CN, with highly probable 
CN in the remainder),60 which were treated with HCO-HD and either bortezomib-
dexamethasone-thalidomide and hematopoietic stem-cell transplantation (HSCT) if 
eligible or bortezomib-melphalan-prednisone in not eligible for HSCT. Of the 21 
patients, 16 became dialysis independent, with sFLC decreases of > 90%. The 3 year 
overall survival was 67%, with no early deaths observed.60 Many other case series 
report similar effectiveness for HCO-HD in renal response.61–64 
Two RCTs have been registered to study the efficacy of HCO-HD in combination with 
bortezomib-based chemotherapy: Studies in Patients With Multiple Myeloma and Renal 
Failure Due to Myeloma Cast Nephropathy (MYRE)65 and the European Trial of Free 
Light Chain Removal by Extended Haemodialysis in Cast Nephropathy (EuLITE).66 
The first, MYRE, recruited 284 patients and aims to compare bortezomib-
dexamethasone with cyclophosphamide + bortezomib-dexamethasone in biopsy proven 
CN patients not requiring HD. In dialysis-dependent patients, the trial will add either 
HCO-HD or conventional high-flux HD to chemotherapy BD. The trial is expected to 
end in September 2017. The second, EuLITE, ended in but its results have yet to be 
published. In the study, 84 patients were randomized to either high-flux HD or HCO-
HD and offered a bortezomib-doxorubicin-dexamethasone chemotherapy regimen. The 
outcomes of both studies include renal response as well as overall survival. 
Other techniques 
Dialysis is a mainstay of acute kidney injury therapy and should be used for the usual 
indications of kidney failure: such as uremia and refractive hyperkalemia. Due to the 
small pore size, FLCs do not diffuse in meaningful quantity across conventional dialysis 
membranes and are therefore not effective in FLC removal. There are reports of FLC 
removal by adsorption onto synthetic polymethylmethacrylate dialysis membranes both 
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in vitro58 and in vivo67,68. These techniques are limited by membrane saturation and 
therefore require either replacing the membrane during renal replacement therapy or 
adding a second one in series. 
Most research regarding high cut-off membranes has been applied to hemodialysis. 
However, the same membranes can be used for hemodiafiltration (HDF). 
A single center prospective cohort study compared hemodiafiltration using a heat 
sterilized high-flux propylene membrane dialyzer with hemodialysis and 
hemodiafiltration using a HCO membrane, in addition to chemotherapy (bortezomib-
based in 75% of patients) in a group of 16 patients with confirmed or probable CN. The 
population included new-onset and relapsed MM. The tracked outcomes were FLC 
reduction ≥ 65%, albumin loss and renal recovery. Of the 10 patients that survived, 9 
were successfully weaned of dialysis. While there was a statistically significant 
difference in lambda FLC reduction between hemodiafiltration with HCO and 
conventional HF-dialyzer – 78 to 61% respectively – both HDF and HCO-HDF were 
effective in reducing kappa FLC in approximately 70% of patients. Albumin losses 
were also much larger with usage of HCO dialyzers, with 21 g/session if HD was 
performed and 63 g/session with HDF. RRT with the conventional dialyzer resulted in a 
loss of only 7 g/session. Importantly, there was no significant difference in renal 
outcome.69 
Another novel approach is hemodiafiltration with endogenous reinfusion of ultrafiltrate 
(SUPRA-HFR) which combines the convection and diffusion of HDF with adsorption. 
A dual chamber dialyzer is used with a first convective stage with a cut-off of 42 kDa 
and a second, diffusive, stage. The ultrafiltrate from the convective stage is circulated 
through a resin cartridge with high affinity for FLCs and reinfused before the second 
stage, thus allowing the adsorption of FLCs and other high protein-bound toxins. This 
technique has been applied to CN-associated kidney injury with two published case 
series, one with 3 and another with 4 patients. In the first,70 one patient became dialysis 
independent, and two did not recover kidney-function. In the second study,71 3 out of 4 
patients achieved reductions of sFLC concentration over 65% and became dialysis 





Myeloma cast nephropathy is the most frequent cause of irreversible renal failure in 
multiple myeloma and associated with a markedly worse prognosis if renal impairment 
persists.23 Studies have shown that a quick decrease in sFLC concentration was 
associated with recovery of renal function72,73, with one study showing that a 60% or 
greater reduction by 21 days of therapy was associated with renal recovery in 80% of 
patients.74 
The role of effective chemotherapy decreasing production of FLCs and therefore 
reducing their concentration is undisputed. However, in renal impairment the FLCs are 
excreted at a reduced rate, leading to their accumulation and perpetuating the end-organ 
damage75. This suggests that extracorporeal removal by mechanical means could be an 
important adjuvant therapy to allow for kidney recovery. The co-precipitating factors of 
cast nephropathy, such as hypercalcemia, dehydration, nephrotoxic drugs and contrast 
agents can lead to overt renal failure in patients with underlying disease. In these cases, 
symptomatic treatment is warranted. 
The affinity of each FLC’s CDR3 for THP is the major determinant in their co-
precipitation and cast formation. Increased FLC concentration in the distal tubule, as 
can occur in dehydration and hypercalcemia, favors this interaction, as do a low pH and 
increased sodium concentration due to loop diuretics. Supportive care aims to create an 
environment less favorable to cast formation. Volume resuscitation, targeting a urine 
output of 3 L/day, and correction of severe hypercalcemia both with bisphosphonates is 
recommended25. Special care should be taken with pamidronate and zoledronate, as 
these are contraindicated in patients with eGFR < 30 mL/min. Denosumab is not 
metabolized by the kidney and can be used in persistent hypercalcemia, but can lead to 
dangerous hypocalcemia. Dialysis is not effective at removing FLCs, but should be 
offered for the usual indications. Urine alkalinization does not appear to improve 
outcomes despite being commonly used.  
Bortezomib-based chemotherapy, particularly with dexamethasone and thalidomide 
(VDT), is the current standard-of-care in patients with new-onset MM and CN76. 
Specifically, the proteasome inhibitor has been shown to rapidly reduce tumor burden 
and FLC production, and in combination with dexamethasone in the first month77 
improves the likelihood of some recovery of renal function. The further addition of 
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immunomodulatory drugs, such as thalidomide or lenalidomide, appears to be 
beneficial. Other proteasome inhibitors may be of benefit in relapsed or refractory 
myeloma. 
Renal impairment does not exclude ASCT or the therapy required49 and patients stand 
to recover renal function, particularly when offered bortezomib.78 However, patients 
with renal impairment have significantly increased transplant-related complications and 
mortality (mortality of 4%, compared to < 1%).48–50 
Because of the delay between institution of chemotherapy and the decrease of sFLC 
concentration, there is a physiological basis for the mechanical removal of FLCs as they 
can potentially reduce the FLC burden immediately.  
Plasmapheresis has been used experimentally for decades with mixed reports of 
effectiveness. Of the 4 RCTs performed, only in one did the study group perform 
significantly better than control.52 The limitations may be due to limited number of 
patients, disparate outcomes or simply outdated methodologies: the trials were 
performed before the widespread availability of bortezomib-based chemotherapy and 
sFLC concentration assays. A case series combining novel agents and plasmapheresis in 
patients with high-probability or biopsy-proven CN showed a significant decrease in 
sFLC concentration and partial or better renal response in 12 of 14 patients.79 However, 
the limitations may instead lie with the technique: plasma exchange sessions are 
typically short (2 hours or less), resulting in limited clearance of the extravascular 
compartment. As much as 85% of  molecules of similar size are retained in the 
extravascular56,58,80, and any benefits might be the result of a good response to 
chemotherapy. Another issue with the technique is the removal of essential proteins 
such as albumin, intact immunoglobulins and clotting factors. As such, the only 
undisputed indication for plasma exchange in MM is hyperviscosity syndrome.81 
High cut-off hemodialysis overcomes many of the limitations of plasmapheresis: the 
membranes used have a cut-off of 50-60 kDa, which is similar to the glomerulus. 
However, due to some lack of pore uniformity, molecules such as albumin are also 
removed, particularly if convection is applied, albeit at a lower rate than the FLCs, 
inflammatory cytokines and myoglobin they were designed to remove. While the 
multiple case series and reports published attest to the effectiveness of HCO-HD in 
combination with chemotherapy – particularly using novel agents – the results from the 
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two ongoing clinical trials should clarify whether there is a benefit to HCO-HD beyond 
that of the chemotherapy. As of now, the data is encouraging: partial renal responses or 
better were  achieved in over 60% of patients treated,82,60,62,59,61 and FLC reduction of 
60-70%.83 There are cases described in which HCO-HD was not effective in clearing 
FLCs due to their aggregation in polymers larger than the membrane cut-off, a 
limitation which had not been previously considered.84 Effectiveness notwithstanding, 
the use of HCO dialyzers is significantly more expensive than other renal replacement 
therapies. A prospective cost-effectiveness study has been published claiming it would 
result in cost savings due to greater life expectancy and savings by avoiding chronic 
hemodialysis, with the caveat of the authors’ significant ties to the dialysis equipment 
manufacturer.85  
While most of recent research has focused on HCO-HD, when hemodiafiltration is 
used, conventional HD membranes can be permeable to FLCs. They may be more 
effective clearing kappa chains, which more frequently present as monomers.69 The 
addition of adsorptive resins to a HDF system allows the reinfusion of the ultrafiltrate 
cleared from FLCs, resulting in an albumin sparing alternative.70,71 These techniques 
hold promise but require further investigation to clarify a potential role and benefits 





• Multiple myeloma is a rare hematological cancer caused by a malignant 
proliferation of plasmatocytes. 
• Cast nephropathy is a frequent complication of multiple myeloma and can often 
be the inaugural presentation of the disease. It is caused by the precipitation of 
immunoglobulin free light chains with Tamm-Horsfall glycoprotein in the distal 
tubule and ascending limb of the loop of Henle. 
• The risk of developing CN is related to the FLC burden, their affinity to THP, 
volume depletion, hypercalcemia, tubular pH, loop diuretics and nephrotoxic 
drugs. 
• Supportive therapy for CN consists in correction of the precipitating factors: 
administration of fluids, bisphosphonates for severe hypercalcemia. 
• Bortezomib based-chemotherapy is the current standard of care for MM 
treatment in patients with CN. Adding dexamethasone to initial therapy, but not 
maintenance therapy, increases the likelihood of renal recovery. Whichever the 
treatment regimen chosen, it should be instituted as quickly as possible to 
increase the likelihood of recovery of renal function. 
• The extracorporeal removal of FLCs is a promising area of investigation but 
conclusive benefits have yet to be proven: 
o Plasmapheresis has been studied the longest, and has so far not shown to 
increase survival or renal recovery. However, most of the studies 
published were performed before the availability of FLC quantification 
and novel agents such as bortezomib so some experts advocate its usage. 
o Hemodialysis using high cut-off membranes appears to be extremely 
effective in rapidly decreasing FLC burden in small case series, and two 
multicentric RCTs are ongoing to evaluate its role. It can be prohibitively 
costly and causes significant albumin loss. 
o Hemodiafiltration may be an effective alternative to HCO-HD, and FLC 
adsorption may have a role to play. Its usage has been very limited up to 
now, but may increase as it is significantly less expensive and causes less 
albumin loss than HCO-HD. 
o Importantly, the mechanical removal of FLCs alone is not sufficient; 
chemotherapy to decrease tumor burden and FLC production is required 
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to improve outcomes. Patients not responding to chemotherapy probably 
do not stand to gain from continued FLC removal. 
• ASCT can be performed in patients with kidney failure, and is associated with 
increased overall survival and renal recovery. However, patients with renal 
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